Transcode CFO Resigns; $1.25M Severance Tied to Future Funding Milestones
RNAZ is trading near its 52-week low of $1.627 (3.9% above the low) on light trading volume (0.3× avg).
Summary
Transcode Therapeutics' CFO resigned effective September 9, 2026, triggering a separation agreement worth up to $1.25 million, with a portion contingent on future funding milestones. John Tattory was appointed interim CFO.
Key Events · Executive and Board Changes · RNAZ
-
CFO Resignation
Thomas A. Fitzgerald resigned as CFO, principal financial officer, principal accounting officer, and board member effective September 9, 2026. The company stated the resignation was not due to any disagreement on operations, policies, or practices.
-
$1.25M Severance Package
The separation agreement provides up to $1,250,000 in severance: $416,667 lump sum within 10 days, $416,667 in monthly installments over 12 months, and a final $416,667 contingent on the company achieving $5 million or $10 million in Qualified Funding within 12 months.
-
Funding-Contingent Payments
The third severance tranche is tied to funding milestones: 50% paid upon $5 million raised, full payment upon $10 million raised, or full payment after 12 months if neither threshold is met. This creates a direct cash obligation linked to the company's capital-raising success.
-
Equity Award to Departing CFO
Fitzgerald received an option to purchase 185,000 shares at the closing price on the separation date, vesting monthly over 12 months with acceleration tied to funding milestones or a sale event. All his outstanding equity awards also became fully vested.
Analysis · RNAZ · Life Sciences
CFO Thomas Fitzgerald resigned from all officer and director roles effective September 9, 2026, and the company agreed to pay up to $1.25 million in severance — a material cash commitment for a company with only $8.4 million in cash and a going-concern warning. The severance is structured in three tranches, with the final $416,667 contingent on the company raising $5 million or $10 million in new funding within 12 months. This ties executive departure costs directly to the company's ability to secure capital, adding pressure to an already tight runway. John Tattory, a veteran biotech CFO consultant, steps in as interim CFO through Stout Risius Ross, providing continuity but at an hourly consulting rate rather than a permanent hire.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNAZ was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.6M. The 52-week trading range was $1.63 to $20.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.